You just read:

Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug

News provided by

Therapix Biosciences

Jan 04, 2017, 09:30 ET